|Awarded On||February 21, 2018|
|Title||Targeting neutrophil elastase as a novel therapy for metastatic breast cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Stephanie Watowich|
This project will investigate a novel approach to treating metastatic breast cancer using new information about how the body’s immune system interacts with the cancer. The project will test the effectiveness of an FDA-approved drug (AZD9668, Alvelestat), which has been developed for chronic obstructive pulmonary disease, in treating metastatic breast cancer using pre-clinical experimental systems. Moreover, the project will examine the efficacy of combination treatment with AZD9668 and an agent (anti-PD-1) that corresponds to additional FDA-approved drug (Pembrolizumab), which is known as an immune checkpoint inhibitor. This combination has the power to unleash the immune system to more effe...